SAB Biotherapeutics (SABS) Change in Receivables (2021 - 2023)
SAB Biotherapeutics (SABS) posted Change in Receivables of -$361735.0 for Q3 2023, up 9.88% on a QoQ basis from -$401388.0 in Q2 2023, and down 110.86% year-over-year from $3.3 million in Q3 2022.
SAB Biotherapeutics (SABS) Change in Receivables (2021 - 2023) Analysis & Trends
SAB Biotherapeutics' Change in Receivables history runs 3 years deep, the most recent figure standing at -$361735.0 for Q3 2023.
- Quarterly Change in Receivables fell 110.86% year-over-year to -$361735.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was -$5.6 million (down 126.42% YoY) and the FY2023 annual result came in at -$5.6 million, down 126.42% from the prior year.
- Change in Receivables was -$361735.0 for Q3 2023 at SAB Biotherapeutics, up from -$401388.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $5.5 million in Q2 2021 and bottomed at -$9.0 million in Q1 2021.
- A 3-year average of -$1.9 million and a median of -$2.2 million in 2022 frame the typical range for Change in Receivables.
- Peak annual rise in Change in Receivables reached 148.28% in 2022, while the deepest fall reached 235.32% in 2022.
- SAB Biotherapeutics' Change in Receivables stood at -$2.2 million in 2021, then slumped by 235.32% to -$7.4 million in 2022, then jumped by 95.1% to -$361735.0 in 2023.
- Business Quant data shows SABS's Change in Receivables at -$361735.0 in Q3 2023, -$401388.0 in Q2 2023, and -$4.8 million in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -361,735.00 |
| Sep 30, 2023 | -361,735.00 |
| Jun 30, 2023 | -401,388.00 |
| Jun 30, 2023 | -401,388.00 |
| Mar 31, 2023 | -4.79 Mn |
| Mar 31, 2023 | -4.79 Mn |
| Dec 31, 2022 | -7.39 Mn |
| Dec 31, 2022 | -7.39 Mn |
| Sep 30, 2022 | 3.33 Mn |
| Sep 30, 2022 | 3.33 Mn |
| Jun 30, 2022 | -2.17 Mn |
| Jun 30, 2022 | -2.17 Mn |
| Mar 31, 2022 | 3.78 Mn |
| Mar 31, 2022 | 3.78 Mn |
| Dec 31, 2021 | -2.20 Mn |
| Dec 31, 2021 | -2.20 Mn |
| Sep 30, 2021 | -6.90 Mn |
| Sep 30, 2021 | -6.90 Mn |
| Jun 30, 2021 | 5.52 Mn |
| Jun 30, 2021 | 5.52 Mn |